|
業務類別
|
Biotechnology |
|
業務概覽
|
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer. |
| 公司地址
| 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138 |
| 電話號碼
| +1 781 806-6245 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.obsidiantx.com |
| 員工數量
| 71 |
|
|